Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTER phase 3 trial of abelacimab versus apixaban in cancer-associated venous thromboembolism
CTR20232550Phase 3Terminated
- Sponsor
- Anthos Therapeutics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of abelacimab in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), sponsored by Anthos Therapeutics. Started May 2024; status: terminated.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on CTR20232550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232550.